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Abstract
Background: Prolonged drug infusions are used to treat horses with severe signs of pain, but can be associated
with altered gastrointestinal transit. The purpose of this study was to determine the effects of prolonged constant
rate infusions (CRI) of lidocaine (L), butorphanol (B), and ketamine (K) alone and in combination on gastrointestinal
transit, behavior, and thermal nociceptive threshold in healthy horses.
Methods: Eight healthy adult horses were used in a randomized, cross-over, blinded, prospective experimental
trial. Interventions were saline, L, K, B, LK, LB, BK, and LBK as an intravenous CRI for 96 hours. Drugs were mixed or
diluted in saline; following a bolus, CRI rate was 0.15mL/kg/hr with drug doses as follows: L – 1.3 mg/kg then 3
mg/kg/hr; B – 0.018 mg/kg then 0.013 mg/kg/hr; K – 0.55 mg/kg then 0.5 mg/kg/hr. Two-hundred plastic beads
were administered intragastrically by nasogastric tube immediately prior to the bolus. Feces were collected every
2 hours, weighed, and beads manually retrieved. Behavior was scored every 2 hours, vital parameters every 6 hours,
and thermal nociceptive threshold every 12 hours for 96 hours. Drug concentrations in the LBK solution were
tested every 6 hours for 72 hours.
Results: Four of 64 trials (3 LBK, 1 BK) were discontinued early due to signs of abdominal discomfort. There were
no apparent differences between groups in vital parameters or thermal threshold. Transit time was delayed for LB
and LBK with a corresponding decrease in fecal weight that was most severe in the final 24 hours of infusion.
Significant changes in behavior scores, vital parameters, or thermal threshold were not observed. The concentration
of each drug in the combined solution declined by less than 31% over the sampling period.
Conclusions: Drug combinations containing butorphanol cause an apparent delay in gastrointestinal transit in
healthy horses without substantially affecting somatic nociception at the doses studied. Combinations of lidocaine
and ketamine may have less impact on gastrointestinal transit than infusions combined with butorphanol. Further
work is needed to determine the effects of these drugs in painful or critically ill patients.
Background
Identification and alleviation of pain is essential for wel-
fare of all species. The most commonly used analgesic
medications in horses include the alpha2-adrenergic ago-
nists, non-steroidal anti-inflammatory drugs (NSAIDs),
and opioids. Despite well-documented analgesic proper-
ties, the alpha2-adrenergic agonists profoundly decrease
gastrointestinal motility [1-3] making these drugs a poor
choice for prolonged administration. NSAIDs can lead
to gastric and colonic ulceration and renal tubular
necrosis, potentially life-threatening side effects. Severe
pain may be refractory to single analgesic therapy; thus
its management may require a multimodal approach,
employing drugs with different mechanisms of action.
Despite the potential for improved analgesia [4], use of
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drug combinations may also increase the potential for
adverse effects, especially alterations in gastrointestinal
motility or behavior [2] when drugs are combined at the
dosages used for monotherapy.
Lidocaine, a local anesthetic, is commonly adminis-
tered as a constant rate infusion (CRI) in horses follow-
ing exploratory laparotomy for its potential analgesic
and prokinetic properties [5-10]. Ketamine, an
N-methyl-D-aspartate (NMDA) receptor antagonist, has
anti-nociceptive properties when administered as a CRI
at sub-anesthetic doses in both anesthetized and con-
scious horses [11,12]. The opioid drug butorphanol, a
kappa (OP2) agonist and competitive mu (OP3) antago-
nist, is commonly administered in the horse with vary-
ing success. No anti-nociceptive properties were noted
in clinically normal horses in response to visceral disten-
sion or noxious thermal stimulus [13] but pain scores
were significantly decreased in horses administered
butorphanol as a constant rate infusion in the immedi-
ate post-operative period following exploratory laparot-
omy [14].
Overall gastrointestinal transit time from the ingestion
of a meal to passage of feces is one of the most clinically
applicable objective evaluations of gastrointestinal func-
tion as it incorporates all segments of the gastrointestinal
tract. It is commonly measured by passage of either
liquid or particulate markers administered via nasogastric
tube, which are then either physically recovered or identi-
fied radiographically in feces [15,16]. Clinical methods for
assessing gastrointestinal motility include auscultation of
gastrointestinal borborygmi and passage of feces. In this
study we combined objective measures of total gastroin-
testinal transit time and fecal output and subjective
assessment of borborygmi scores for a global assessment
of gastrointestinal motility.
Thermal threshold (TT) testing has been successfully
used in adult horses and foals to evaluate somatic noci-
ception [10,17,18]. A wireless TT system allows testing to
be performed with the horse unrestrained, [17] which
allows the horse to display the full range of behavioral
responses to a noxious stimulus and reduces the poten-
tial effects of restraint and presence of an investigator on
the response. Thermal nociceptive threshold testing is
one measure of nociception. The benefits of this mode of
testing are that it is repeatable and causes no tissue
damage thus reducing the animal welfare concerns with
repeated nociceptive testing.
The purpose of the study reported here was to evaluate
the effects of lidocaine, ketamine, and butorphanol, alone
and in combination, on total gastrointestinal transit time,
somatic nociception, and behavior in clinically normal
horses. From an immediate clinical standpoint, this study
provides clinicians already using these drugs in combina-
tion with knowledge of both the anti-nociceptive and
systemic effects of the medications in healthy, non-pain-
ful, horses.
Methods
Animals
Eight Thoroughbred or Thoroughbred-cross horses
(5 geldings, 3 mares; aged 5-20 years; weight 463-558 kg)
were used. Each horse was instrumented with a perma-
nent gastric cannula placed for the purpose of other
experiments. Mares were used during behavioral diestrus.
There was at least 1 week between the end of one study
period and the beginning of the next, during which
horses were maintained on grass pasture with concen-
trate and grass hay available. All experimental procedures
were approved by the University of Florida Institutional
Animal Care and Use Committee.
Horses were stalled 12-18 hours prior to each study
period for acclimation. Horses were studied in groups of
2-3 to reduce the effects of social isolation on study out-
come. Body weight was measured following acclimation
and at the end of each study. Horses were offered free
choice grass hay (in pre-weighed bins) and water (in
graduated buckets) and twice-daily concentrate during
the course of the study. Hay and water consumption was
measured and recorded every 4 hours throughout the
study period.
Treatments
Each study period began between 0800 and 1000 hours.
Each horse received each treatment in an orthogonal
Latin square design; investigators were blinded as
to treatment. Treatments were 0.9% sodium chloride
(Placebo, P; 60 mL bolus, 0.15 mL/kg/hr), lidocaine
hydrochloride (Lidocaine hydrochloride injectable-2%,
Phoenix Pharmaceutical, Inc., St. Joseph, MO, USA) (L;
1.3 mg/kg bolus, 3 mg/kg/hr), ketamine hydrochloride
(KetaVed®, Vedco, St. Joseph, MO, USA) (K; 0.55 mg/kg
bolus, 0.5 mg/kg/hr), butorphanol tartrate (Torbugesic®,
Fort Dodge Animal Health, Fort Dodge, IA, USA) (B;
0.018 mg/kg bolus, 0.013 mg/kg/hr) administered indivi-
dually and in combination (P, L, B, K, LK, LB, KB, and
LBK) for a total of 8 treatments. No diluent was needed
for treatments including lidocaine; all other drugs and
combinations were diluted in sodium chloride. Infusions
were prepared in 1-L increments. The bolus was adminis-
tered over 15 minutes and the CRI administration began
immediately following the bolus with a computerized
infusion pump for 96 hours.
Drug stability
Prior to the live animal study, stability of the drugs in
combination was assessed. Ketamine and butorphanol
were added to lidocaine (100 mL total volume) at the
dosage indicated for LBK infusion. The drug combination
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was maintained inside in a climate controlled environ-
ment at room temperature (approximately 20-22ºC) in
ambient light. A 2mL sample was removed and frozen at
-20ºC every 6 hours for 72 hours. The concentrations of
butorphanol, lidocaine and ketamine were determined by
liquid chromatography (Shimadzu Prominence,
Shimadzu Scientific Instruments, Columbia, MD, USA)
and mass spectrometry (API 2000, Applied Biosystems,
Foster City, CA, USA). The internal standards were fen-
tanyl (Cerilliant Corporation, Round Rock, TX, USA),
mepivacaine (Sigma-Aldrich, St Louis, MO, USA), and
ketamine d4 (Cerilliant Corporation, Round Rock, TX,
USA) for butorphanol, lidocaine and ketamine respec-
tively. The qualifying and quantifying ions for butorpha-
nol, lidocaine and ketamine were mass to charge ratio
(m/z) 328.21®157.2, 235.22®86.2, and 238.09®124.9,
respectively. The qualifying and quantifying ions for fen-
tanyl, mepivacaine and ketamine d4 were (m/z)
337.14®105.3, 247.21®98.2, and 242.16®129.1, respec-
tively. Standard curves for each of the analytes were
accepted if they were linear with calculated concentra-
tions within 15% of the actual concentration and the cor-
relation coefficient was at least 0.99. The standards and
the tested solutions were diluted in 0.1% formic acid in
water. The mobile phase consisted of A: acetonitrile and
B: 0.1% formic acid in deionized water at a flow rate of
0.4 mL/min. The mobile phase started at 90% B with a
linear gradient to 40% B at 4 minutes and back to 90% B
at 5 minutes with a total run time of 6.5 minutes. Separa-
tion was achieved with a C18 column (ACE C18AR, 150
mm x 3.0 mm x 5 μm) (MAC-MOD Analytical, Chadds
Ford, PA, USA) maintained at 40°C.
Data collection
For each trial, a 14-g intravenous catheter was placed
aseptically into each jugular vein and horses were fitted
with a fecal collection device. A nasogastric tube was
placed and 200 3x5-mm plastic beads administered in
1 L water by gravity flow using a funnel. Different color
beads were used for each trial to avoid any carryover
from previous trials. After bead administration was com-
plete, treatment bolus then CRI began. Vital signs (heart
rate, respiratory rate, and rectal temperature), behavior
scores, and gastrointestinal borborygmi scores were
recorded as previously described [19] every 6 hours for
the study duration. Feces were collected, weighed, and
beads manually retrieved every 2 hours. Following
retrieval of 180 beads, the fecal collection device was
removed and feces collected from the stall floor were
weighed every 2 hours. Hay (kg) and water (L) con-
sumption was recorded every 6 hours.
Thermal threshold (TT) testing was performed using a
wireless device as previously described [17]. Briefly, an
area on one side of the withers (alternating randomly)
was shaved and the TT probe placed in direct contact
with the skin. The probe was secured using an adjusta-
ble nylon strap around the thorax. Consistent pressure
between the probe and skin was ensured by inflating a
modified blood pressure cuff and pressure monitored by
a sensor within the device. Skin temperature was
recorded following an equilibration period of at least
5 minutes. The device was activated by a wireless hand-
held toggle switch by an investigator positioned outside
of the horse’s stall. The device was activated when the
horse was not visibly interacting with the investigator.
Heating was discontinued either when the horse dis-
played a response or at 55ºC, whichever occurred first.
Responses included a skin twitch, looking at the flank,
or an abrupt lifting of the head. TT was performed
twice prior to treatment bolus (baseline), 15 minutes
into the drug infusion then every 12 hours for the dura-
tion of the study. TT was not performed on one horse
due to its failure to respond to the stimulus at the base-
line measurement. For time points reaching the cut-off
value (55ºC), responses were recorded as 55.5 for data
analysis.
Statistical analysis
Unless indicated otherwise, all data are expressed as
least square mean ± standard error of the mean. For
TT, baseline was considered the mean of two measure-
ments. The data for each response variable conformed
to a split-plot ANOVA according to the model: Y =
Treatment + Period + Horse + Error1 + Time + Treat-
ment*Time + Error2. When period was not a significant
factor for a given response variable, period was elimi-
nated from each model and data were then analyzed by
a three-factor ANOVA with the fixed factors of Time
and Treatment and the random factor of Horse. When
significant main effects or interactions occurred, post
hoc comparisons were made by the Bonferroni t test.
A commercial software package (SAS/STAT, SAS Insti-
tute Inc., Cary, NC, USA) was used for all analyses and
a p < 0.05 was considered significant. For post hoc com-
parisons, the critical p was considered 0.05/number of
comparisons.
Mean fecal bead passage fit to a four-parameter logis-
tic equation (SigmaPlot 11.0, Systat Software, Inc., San
Jose, CA, USA) that was then used to calculate the time
to passage of 1, 25, 50, and 75% of beads for each treat-
ment via regression.
Results
The infusion was discontinued for 3 horses in the LBK
group (after a mean of 38 hours) and 1 in the BK group
(after 16 hours) due to signs of colic; their data were
excluded from analysis. Signs of pain were mild in all
horses (flank watching, lying down), none developed
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nasogastric reflux, and all responded to medical therapy
(flunixin meglumine, water and electrolytes via nasogas-
tric tube). No other problems were observed.
The percentage of active drug, relative to time 0,
detected in the combined solution (as prepared for all
infusions) after 6, 12, 24, 48, and 72 hours of storage
was as follows: butorphanol - 78, 92, 81, 83, 79%; keta-
mine - 72, 90, 75, 74, 69%; lidocaine - 88, 93, 108, 85,
87%. Each 1L bag was administered within 15 hours.
Mean fecal bead passage logistic regression curves are
presented in Figure 1; time to passage of 1, 25, 50, and
75% of beads (T1, T25, T50, T75) are presented in Table 1.
Transit time was significantly delayed in the LB and LBK
groups.
Overall, horses receiving treatments containing butor-
phanol had decreased fecal output relative to horses
receiving other infusions (Table 2). This was most evi-
dent in the LB group within 36-48 hours and in the
other butorphanol-containing groups by 72-84 hours.
There was no significant treatment effect on thermal
threshold (Table 3), any vital parameter, behavior or
gastrointestinal borborygmi scores, or hay or water con-
sumption (data not shown). There were significant time
and/or period effects on skin temperature, rectal tem-
perature, borborygmi scores, heart rate, and body
weight. Skin and rectal temperatures were higher in the
early experimental periods (the order of experiments,
regardless of drug administered) (Figure 2). Body weight
was significantly lower in periods 1 and 2 (492.0±9.5
and 494.1±9.4 kg, respectively) relative to periods 4-6
(508.9±9.5, 509.4±9.4, 507.7±9.5 kg). Borborygmi scores
were lower in periods 1-3 (7.3±0.6, 7.3±0.6, 6.3±0.6),
relative to 5-8 (10.6±0.6, 10.6±0.6, 10.8±0.6, 11.2±0.6).
Heart rate was higher in period 1 (41.9±1.2 bpm),
relative to periods 5 (37.0 ± 1.2) and 7 (36.9 ± 1.2) and
tended to increase then decrease over the 96-hour study
period. Skin and rectal temperatures also had a signifi-
cant time effect, such that temperatures were higher in
the afternoon/evening (Figure 3).
The study was conducted from June 2010 through
February 2011. Temperature data for the mean date for
each study period presented in Table 4.
Discussion
We report a significant delay in total gastrointestinal
transit time and a decrease in cumulative fecal weight as
a result of prolonged continuous rate infusion with lido-
caine/butorphanol and lidocaine/ketamine/butorphanol
combinations. Each drug combination containing butor-
phanol caused a decrease in cumulative fecal weight
during the latter portion of the infusion. The negative
effects on cumulative fecal weight do not appear asso-
ciated with decreased intake, as neither hay nor water
consumption was significantly affected.
An infusion time of 96 hours was chosen to ensure
that all beads passed during drug infusion. While this
duration of infusion may be longer than that com-
monly used for post-operative patients, horses experi-
encing severe pain (i.e. laminitis, pleuropneumonia,
orthopedic trauma) may require multimodal analgesic
therapy of prolonged duration. In fact, we observed sig-
nificant effects on fecal passage only in the last 24
hours of the 96-hour period with butorphanol, butor-
phanol/ketamine, and lidocaine/butorphanol/ketamine,
whereas there were no substantial effects of these drug
combinations (except LBK at T25) on bead passage.
This suggests that the effects of drug combinations on
gastrointestinal motility worsen with longer duration of
administration.
Figure 1 Four parameter logistic regression equations
generated from the mean of beads collected in feces over
time after intragastric administration (200 beads). See Table 1
for key to treatments.
Table 1 Mean ± SD time (hours) to passage of 1 (T1), 25
(T25), 50 (T50), and 75 (T75)% of beads after intragastric
administration (200 beads).
T1 T25 T50 T75
P 14.1 ± 4.5a 27.3 ± 5.9a 35.1 ± 9.1a 42.2 ± 11.0
L 16.0 ± 5.7a 29.2 ± 9.4a,c 38.2 ± 17.7a,b 41.6 ± 12.9
B 15.8 ± 5.2a,b 31.1 ± 6.9a,b,c 36.3 ± 7.2a,b 43.5 ± 7.5
K 14.7 ± 4.1a 28.6 ± 8.8a 36.7 ± 12.3a,b 48.7 ± 18.8
LB 24.5 ± 9.9b 41.2 ± 13.4b,c 45.5 ± 10.9b 57.3 ± 14.3
LK 15.2 ± 3.5a 28.4 ± 7.0a 35.1 ± 9.0a 42.6 ± 11.6
BK 21.0 ± 10.0a,b 33.2 ± 10.8a,b,c 35.9 ± 5.9a,b 44.7 ± 6.2
LBK 19.5 ± 7.6a,b 34.0 ± 9.1b,c 40.2 ± 11.0a,b 52.4 ± 20.7
Within a column, different superscripts indicate significant difference between
groups. Underlined and bolded font indicates significant difference from
placebo. Treatments included infusions of 0.9% saline (Placebo, P), lidocaine
(L), butorphanol (B), and ketamine (K); added letters indicates drugs
administered in combination (i.e. LB signifies administration of lidocaine and
butorphanol in combination).
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A significant treatment effect was not evident for any
other measured parameter. Significant period and time
effects were observed with rectal temperature, skin tem-
perature and heart rate; a significant period effect was
noted with body weight. The changes in skin and rectal
temperature appear related to ambient temperature and/
or relative humidity, as temperatures were higher in the
afternoon/evening hours and during the summer
months. These effects were small and likely clinically
insignificant, and did not apparently affect treatment or
time-treatment interactions because of the orthogonal
study design.
Data for the LBK group represent only 5 horses, as the
infusion was discontinued in 3 due to colic. Although
decreased fecal output and delayed transit were still evi-
dent in this group, the negative effects on gastrointest-
inal function may have been underestimated because the
3 omitted horses likely had the most severely altered
gastrointestinal function, resulting in colic. In addition,
these horses still displayed signs of abdominal pain
despite receiving all three putative analgesic agents
together, suggesting either limited visceral analgesia
with this drug combination or overriding abdominal
pain. Alternatively, it is possible that affected horses
experienced some degree of analgesia thus continued to
eat hay despite developing ileus, until a more severe
problem developed. In prior studies, we were unable to
demonstrate visceral anti-nociceptive effects with lido-
caine [10] or butorphanol [13] administered as a CRI to
healthy horses. It is not known whether anti-nociceptive
properties would exist with this drug combination in ill
or painful horses.
A significant decrease in cumulative fecal weight for
each combination including butorphanol was observed
in the current work. We also observed a decrease in
fecal weight during the final 24 hours of the 96-hour
infusion for horses treated with butorphanol alone, after
all of the beads had been passed. This supports prior
work in healthy horses [20] and horses post-celiotomy
[14], which also showed decreased fecal output. But, in
healthy horses, a short duration butorphanol CRI did
not significantly alter duodenal motility [13]. The
observed decrease in fecal weight and prolonged passage
of beads for combinations that included butorphanol
may be due to numerous factors including the potential
for accumulation of any drug or its metabolites during
the infusion, competitive metabolism, or a potential
synergistic inhibitory effect on motility of drugs given in
Table 2 Mean (±SD) cumulative fecal weight (kg) passed over time.
Time (hr)
0-12 13-24 25-36 37-48 49-60 61-72 73-84 85-96
P 10.9±2.6 20.8±4.9 29.0±6.3a,b 38.9±7.5a 47.5±10.0a 57.2±11.0a 65.1±14.6a 75.6±17.6a
L 8.2±2.8 17.8±6.2 25.5±8.0a,b 33.9±10.3a,b 40.1±11.6a,b 48.0±15.2a,b 54.3±17.6a,b 62.2±21.6a,b
B 6.9±3.5 17.5±6.3 24.6±8.9a,b 34.4±11.0a,b 40.7±13.0a,b 48.3±15.8a,b 52.8±17.7b,c 60.6±20.8b,c
K 10.3±3.0 21.6±6.9 29.8±9.5a 39.7±13.6a 48.8±18.0a 59.2±22.3a 66.3±26.2a 75.4±29.9a
LB 3.7±2.3 10.9±4.7 16.8±6.3b 24.6±8.0b 30.2±10.0b 37.0±12.8b 41.5±15.0c 47.6±18.2c
LK 9.3±1.7 20.3±5.3 29.3±7.9a,b 39.5±10.6a 48.0±14.5a 59.0±18.2a 66.4±21.8a 75.4±23.4a
BK 6.9±3.4 16.4±5.8 23.3±8.1a,b 31.8±10.5a,b 38.6±12.9a,b 46.5±16.2a,b 52.0±20.2a,b,c 60.2±23.9b
LBK 5.2±3.9 12.7±9.4 18.1±13.8a,b 25.2±17.7a,b 33.3±22.8a,b 39.8±27.6a,b 45.4±31.9a,b,c 50.9±36.1b,c
Within a column, different superscripts indicate significant difference between groups. Underlined and bolded font indicates significant difference from placebo.
See Table 1 for key to treatments.
Table 3 Mean (±SD) thermal threshold (ºC).
Time (hr)
-0.5 -0.25 0.5 6 12 24 36 48 60 72 84 96
P 45.7 ±3.4 50.0 ±4.5 52.5 ±3.2 46.4 ±3.9 49.2 ±4.8 51.7 ±4.0 50.8 ±3.8 47.3 ±3.5 51.8 ±3.0 49.7 ±2.3 51.3 ±2.0 52.0 ±4.5
L 47.2 ±1.9 46.9 ±3.0 52.5 ±2.8 49.7 ±3.6 52.2 ±4.1 49.7 ±4.6 50.9 ±2.7 49.2 ±1.4 49.7 ±4.1 51.1 ±3.7 53.2 ±2.5 49.0 ±3.3
B 50.5 ±3.5 49.0 ±3.9 47.9 ±4.2 49.1 ±2.6 52.1 ±2.7 50.8 ±2.7 51.2 ±3.5 50.4 ±3.2 49.1 ±2.5 52.3 ±3.5 53.3 ±2.5 51.1 ±5.2
K 47.0 ±4.1 47.4 ±5.1 48.4 ±5.3 47.8 ±2.4 49.3 ±5.5 50.3 ±2.6 49.7 ±3.4 49.2 ±1.8 52.2 ±3.7 52.1 ±2.8 50.1 ±3.3 49.4 ±4.5
LB 46.4 ±3.8 48.1 ±2.4 53.7 ±2.9 50.1 ±3.8 50.2 ±3.7 51.3 ±2.2 49.8 ±1.0 50.7 ±3.6 49.8 ±3.5 52.0 ±3.2 49.4 ±6.2 52.6 ±2.9
LK 48.7 ±3.0 47.3 ±3.5 53.6 ±2.7 48.1 ±4.3 49.5 ±3.3 49.8 ±3.9 47.6 ±5.6 49.9 ±5.4 49.1 ±4.5 49.7 ±2.4 52.1 ±2.0 49.4 ±3.7
BK 46.2 ±2.6 51.2 ±4.4 50.6 ±3.8 47.5 ±2.8 50.5 ±3.6 48.4 ±3.2 49.7 ±4.8 50.1 ±1.8 50.6 ±3.5 50.7 ±2.8 51.0 ±3.6 51.6 ±3.9
LBK 46.1 ±2.3 45.6 ±5.5 49.7 ±4.4 48.8 ±3.4 51.4 ±3.9 49.1 ±5.0 51.3 ±3.8 49.8 ±1.9 49.2 ±5.0 50.3 ±4.9 48.1 ±5.2 51.6 ±4.9
See Table 1 for key to treatments. No significant period, time, or treatment effects were detected.
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combination. Further evaluation of the effects of butor-
phanol and its metabolites and lidocaine and metabolites
on the equine gastrointestinal tract in combination are
warranted.
The reported effects of lidocaine administration on
gastrointestinal motility in the horse have been variable.
Lidocaine administration following exploratory laparot-
omy has been associated with reduced small intestinal
diameter and peritoneal fluid accumulation [8],
decreased duration of gastric reflux and hospital stay
[7], and reduced incidence of post-operative ileus and
improved survival [21]. However, in normal horses lido-
caine causes decreased jejunal motility [6] and delayed
gastrointestinal transit time after prolonged administra-
tion [22]. In this study, we observed no effects of a pro-
longed lidocaine CRI on gastrointestinal transit, except
when combined with butorphanol.
Figure 2 Least square mean skin (A) and rectal (B)
temperatures for each study period. A study period corresponds
to the treatment order for each horse and includes data regardless
of treatment administered. The mean start date for study periods 1-
8 was as follows: 28 June, 20 July, 15 August, 28 September, 24
October, 17 November, 2 February, and 21 February. Asterisk (*)
indicates significant difference from period 1; # indicates significant
difference from period 2. Error bars represent SEM.
Figure 3 Least square mean skin (A) and rectal (B)
temperatures for each study time. The study time corresponds to
the time after bead administration (time 0) and includes data for all
horses and all treatments. See figure 2 for key to indication of
statistical significance. Time 0 was between 0800 and 1000 hours.
Error bars represent SEM.
Table 4 Ambient temperature, humidity, and dew point
at representative dates for each study period.
Period Mean start
date
High
(ºC)
Low
(ºC)
Mean humidity
(%)
Dew point
(ºC)
1 28-Jun 2010 33.3 23.3 75 22.8
2 20-Jul 2010 34.4 24.4 70 23.3
3 15-Aug 2010 33.3 23.9 79 24.4
4 28-Sep 2010 33.3 23.3 79 21.1
5 24-Oct 2010 31.7 12.8 64 14.4
6 17-Nov 2010 24.4 8.3 69 13.9
7 2-Feb 2011 23.9 13.9 75 17.2
8 21-Feb 2011 27.8 11.1 69 13.3
Data represent the daily high and low temperature, mean humidity, and dew
point for the mean start date of each study period for Gainesville, FL accessed
through http:\\www.wunderground.com.
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In human and small animal intensive care units, sub-
anesthetic doses of ketamine are commonly used for
multi-modal pain management and it is believed that
ketamine has few adverse systemic effects [23]. Sub-
anesthetic doses of ketamine, when administered as con-
stant rate infusions, significantly decreased overall gas-
trointestinal transit time in comparison with saline
control in a prior study [19]. In the study reported here,
a lower dose of ketamine was used with no observed
adverse effects on behavior scores or total gastrointest-
inal transit. However, along with the lack of adverse
effects, there were no demonstrated anti-nociceptive
effects associated with infusions of any drug or combi-
nation at dosages used in this study. The lack of antino-
ciceptive effects of ketamine may be due to the lack of
central sensitization in these non-painful animals.
Further studies in animals with existing pain are war-
ranted and may assess the antinociceptive effects of
ketamine infusion more accurately.
Conclusions
The results of this study, although performed in clini-
cally normal horses, have potential direct clinical appli-
cation. First, the negative effects of drug combinations
on fecal weight began within 36 hours, but apparently
worsened with prolonged infusion duration. Second, 3
of the 8 clinically normal horses receiving a combined
infusion of lidocaine, butorphanol, and ketamine devel-
oped colic. Lidocaine and butorphanol in combination
also resulted in a severe delay in gastrointestinal transit
and reduced fecal weight, but not colic. Finally, despite
the observed delay in gastrointestinal transit, there was
no apparent effect on gastrointestinal borborygmi
scores. This highlights the poor sensitivity of gastroin-
testinal borborygmi as a sole clinical marker of gastroin-
testinal motility. These results are consistent with those
of a previous study that showed poor agreement of aus-
cultation scores with electrointestinography [24]. Thus,
clinicians using lidocaine, butorphanol, and ketamine in
combination should carefully monitor fecal output and
be aware of the potential for colic in these patients. The
reader should also note that the doses studied likely
represent the maximal dosage used, and the effects
upon gastrointestinal motility may be limited if lower
dosages are used in combination. The lack of observed
thermal threshold effects likely represent a lack of drug
effect on thermal nociception at doses used in this
study. Thermal nociceptive threshold testing is only one
measure of nociception and may poorly recapitulate
severe clinical pain. Further work is required to deter-
mine the effects of these drugs in combination on noci-
ception and gastrointestinal motility in critically ill and
painful horses.
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